Strengthening our position as leaders in labeling and detection, Enzo Life Sciences now offers Digoxigenin-dUTP and Digoxigenin-UTP, digoxigenin-labeled nucleotides that are suitable for a variety of molecular biology applications.
Digoxigenin is a non-radioactive immune-tag, widely used for in situ hybridization (ISH) and protein labeling. It can be paired with anti-digoxigenin antibodies to allow the detection of interested biomolecules with high affinity and specificity. Digoxigenin-based detection overcomes high background or false positives that may arise from endogenous biotin in biological samples when using biotin-based detection.
Digoxigenin-dUTP and Digoxigenin-UTP can be used to produce digoxigenin-labeled nucleic acid probes in a variety of labeling reactions. The resulting digoxigenin-labeled probe can be used in a wide range of hybridization applications incuding in situ hybridizations, Southern blots, Northern blots, or dot blots.
For more information, or to order the Digoxigenin dUTP, Digoxigenin UTP, or other Enzo Life Sciences products, please visit us at www.enzolifesciences.com or call us at 1-800-942-0430.
Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products and services that meet the ever-changing and rapidly growing needs of healthcare. Underpinning Enzo Biochem’s technologies, platforms and products is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Enzo Life Sciences, Inc. is a pioneer in labeling and detection technologies from genome to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities.
New Product Release
Date: March 10th 2016
For additional Information, please contact:
Kara Cannon, Global Head of Marketing
1-631-694-7070 x 145
